Deal Making

Featured on Deal Making

Novo Nordisk to convert Purdue NC plant to make oral diabetes drug
Facilities & Capacity
Novo Nordisk to convert Purdue NC plant to make oral diabetes drugNovo Nordisk to convert Purdue NC plant to make oral diabetes drug

Novo Nordisk will rebuild a facility in Treyburn, North Carolina acquired from Purdue Pharma to support an oral form of its GLP-1 analogue semaglutide.

byDan Stanton
Aug 5, 2019
|
2 Min Read
Challenging the vaccine space: The problem with pioneers
Global Markets
Challenging the vaccine space: The problem with pioneersChallenging the vaccine space: The problem with pioneers
byBPI Staff
Aug 1, 2019
3 Min Read
Danaher: ‘All indications show GE is in wonderful shape’
Upstream & Downstream Processing
Danaher: ‘All indications show GE is in wonderful shape’Danaher: ‘All indications show GE is in wonderful shape’
byDan Stanton
Jul 31, 2019
2 Min Read
Big Pharma M&A a boon for business, says Thermo Fisher
Global Markets
Big Pharma M&A a boon for business, says Thermo FisherBig Pharma M&A a boon for business, says Thermo Fisher
byDan Stanton
Jul 30, 2019
2 Min Read
VGXI to supply plasmid for Geneos’ cancer DNA vaccines
Deal-Making
VGXI to supply plasmid for Geneos’ cancer DNA vaccinesVGXI to supply plasmid for Geneos’ cancer DNA vaccines
byDan Stanton
Jul 23, 2019
2 Min Read
Pall to provide ‘A-Z of single-use tech’ in Servier deal
Upstream & Downstream Processing
Pall to provide ‘A-Z of single-use tech’ in Servier dealPall to provide ‘A-Z of single-use tech’ in Servier deal
byDan Stanton
Jul 19, 2019
2 Min Read

More from Deal Making

Boehringer to buy cancer vaccine firm AMAL for €325m
Deal-Making
Boehringer to buy cancer vaccine firm AMAL for €325m
Boehringer to buy cancer vaccine firm AMAL for €325m
Jul 16, 2019
|
2 Min Read
byBPI Staff
Rights of Passage: Paragon building dedicated gene therapy suite
Facilities & Capacity
Rights of Passage: Paragon building dedicated gene therapy suite
Rights of Passage: Paragon building dedicated gene therapy suite
Jul 12, 2019
|
2 Min Read
byDan Stanton
Instrumental deal: Agilent to bolster cell analysis biz with BioTek buy
Deal-Making
Instrumental deal: Agilent to bolster cell analysis biz with BioTek buy
Instrumental deal: Agilent to bolster cell analysis biz with BioTek buy
Jul 12, 2019
|
2 Min Read
byDan Stanton
Investment digest: News from Pfizer, Bayer and Altimmune
Deal-Making
Investment digest: News from Pfizer, Bayer and Altimmune
Investment digest: News from Pfizer, Bayer and Altimmune
Jul 10, 2019
|
2 Min Read
byBPI Staff
M&A hungry BioLife to buy cold-chain services firm SAVSU
Deal-Making
M&A hungry BioLife to buy cold-chain services firm SAVSU
M&A hungry BioLife to buy cold-chain services firm SAVSU
Jul 9, 2019
|
2 Min Read
byDan Stanton
Ohr pushes for oligonucleotide merger with NeuBase
Deal-Making
Ohr pushes for oligonucleotide merger with NeuBase
Ohr pushes for oligonucleotide merger with NeuBase
Jul 5, 2019
|
2 Min Read
byBPI Staff
Lonza takes parenteral control through Novartis plant buy and contract
Facilities & Capacity
Lonza takes parenteral control through Novartis plant buy and contract
Lonza takes parenteral control through Novartis plant buy and contract
Jul 2, 2019
|
2 Min Read
byDan Stanton
Amicus contracts Thermo Fisher to make Batten disease gene therapy
Deal-Making
Amicus contracts Thermo Fisher to make Batten disease gene therapy
Amicus contracts Thermo Fisher to make Batten disease gene therapy
Jul 2, 2019
|
2 Min Read
byBPI Staff
AbbVie: Lack of Botox biosimilars a factor in $63bn Allergan buy
Therapeutic Class
AbbVie: Lack of Botox biosimilars a factor in $63bn Allergan buy
AbbVie: Lack of Botox biosimilars a factor in $63bn Allergan buy
Jul 1, 2019
|
3 Min Read
byDan Stanton
$63bn Allergan deal: ‘Humira is buying the assets that will replace it’
Deal-Making
$63bn Allergan deal: ‘Humira is buying the assets that will replace it’
$63bn Allergan deal: ‘Humira is buying the assets that will replace it’
Jun 26, 2019
|
3 Min Read
byDan Stanton
Eli Lilly on R&D: Two thirds internal, one third external
Deal-Making
Eli Lilly on R&D: Two thirds internal, one third external
Eli Lilly on R&D: Two thirds internal, one third external
Jun 21, 2019
|
2 Min Read
byDan Stanton
Biotech money: Global funding down despite spate of IPOs
Global Markets
Biotech money: Global funding down despite spate of IPOs
Biotech money: Global funding down despite spate of IPOs
Jun 21, 2019
|
2 Min Read
byBPI Staff
Celgene pays BeiGene $150m as it hands back anti-PD-1 rights
Deal-Making
Celgene pays BeiGene $150m as it hands back anti-PD-1 rights
Celgene pays BeiGene $150m as it hands back anti-PD-1 rights
Jun 19, 2019
|
2 Min Read
byDan Stanton
Alpine inks iPSCs vision lost therapy deal with Allele
Deal-Making
Alpine inks iPSCs vision lost therapy deal with Allele
Alpine inks iPSCs vision lost therapy deal with Allele
Jun 18, 2019
|
2 Min Read
byDan Stanton
Amgen: ‘We’ve shaved 3 years off development but can do better’
Global Markets
Amgen: ‘We’ve shaved 3 years off development but can do better’
Amgen: ‘We’ve shaved 3 years off development but can do better’
Jun 17, 2019
|
2 Min Read
byDan Stanton
Servier selects Yposkesi for viral vector supply
Deal-Making
Servier selects Yposkesi for viral vector supply
Servier selects Yposkesi for viral vector supply
Jun 11, 2019
|
2 Min Read
byDan Stanton
Merck in $773m deal to add preclinical MAb firm Tilos
Deal-Making
Merck in $773m deal to add preclinical MAb firm Tilos
Merck in $773m deal to add preclinical MAb firm Tilos
Jun 11, 2019
|
1 Min Read
byBPI Staff
Rexgenero adds CMO to speed up cell therapy trials
Deal-Making
Rexgenero adds CMO to speed up cell therapy trials
Rexgenero adds CMO to speed up cell therapy trials
Jun 4, 2019
|
2 Min Read
byDan Stanton
PE to boost Vibalogics’ viral vector capabilities
Deal-Making
PE to boost Vibalogics’ viral vector capabilities
PE to boost Vibalogics’ viral vector capabilities
Jun 2, 2019
|
2 Min Read
byDan Stanton
Affibody contracts 3P for psoriasis protein scale-up
Deal-Making
Affibody contracts 3P for psoriasis protein scale-up
Affibody contracts 3P for psoriasis protein scale-up
Jun 2, 2019
|
2 Min Read
byBPI Staff
Zolgensma approval marks success for REGENXBIO’s vector platform
Therapeutic Class
Zolgensma approval marks success for REGENXBIO’s vector platform
Zolgensma approval marks success for REGENXBIO’s vector platform
May 29, 2019
|
2 Min Read
byDan Stanton
Novartis to end $300m a year facility services deal with ISS
Deal-Making
Novartis to end $300m a year facility services deal with ISS
Novartis to end $300m a year facility services deal with ISS
May 28, 2019
|
1 Min Read
byBPI Staff
ProBioGen licenses duck cell line tech to Vaccitech for viral vaccines
Bioprocess Insider
ProBioGen licenses duck cell line tech to Vaccitech for viral vaccines
ProBioGen licenses duck cell line tech to Vaccitech for viral vaccines
May 24, 2019
|
2 Min Read
byDan Stanton
WuXi scouts single-use site for Chinese vaccine joint venture
Global Markets
WuXi scouts single-use site for Chinese vaccine joint venture
WuXi scouts single-use site for Chinese vaccine joint venture
May 22, 2019
|
2 Min Read
byDan Stanton
Evotec lays down $90m to buy Just for kickstarting biologics biz
Deal-Making
Evotec lays down $90m to buy Just for kickstarting biologics biz
Evotec lays down $90m to buy Just for kickstarting biologics biz
May 21, 2019
|
2 Min Read
byBPI Staff
Cryoport acquires Cryogene for $20.5m, adds Texas biostorage site
Deal-Making
Cryoport acquires Cryogene for $20.5m, adds Texas biostorage site
Cryoport acquires Cryogene for $20.5m, adds Texas biostorage site
May 17, 2019
|
2 Min Read
byDan Stanton
CDMO round-up: News from Patheon, Samsung and Sekisui
Deal-Making
CDMO round-up: News from Patheon, Samsung and Sekisui
CDMO round-up: News from Patheon, Samsung and Sekisui
May 15, 2019
|
3 Min Read
byBPI Staff
Fungal infection? Biopharma embrace boosts Dyadic’s high titer platform
Deal-Making
Fungal infection? Biopharma embrace boosts Dyadic’s high titer platform
Fungal infection? Biopharma embrace boosts Dyadic’s high titer platform
May 15, 2019
|
3 Min Read
byDan Stanton
Subcutaneous success a boon for Halozyme, but biosimilars hit royalties
Global Markets
Subcutaneous success a boon for Halozyme, but biosimilars hit royalties
Subcutaneous success a boon for Halozyme, but biosimilars hit royalties
May 10, 2019
|
3 Min Read
byDan Stanton
Bayer plans $150m Californian biologics plant, creating 100 jobs
Deal-Making
Bayer plans $150m Californian biologics plant, creating 100 jobs
Bayer plans $150m Californian biologics plant, creating 100 jobs
May 10, 2019
|
2 Min Read
byDan Stanton

Webinars

Ask the Expert webcasts
ATE Webcasts
Register Now: Introducing Super Refined™ Poloxamer 188: Optimized for Mammalian Cell Culture with Exceptional Batch-to-Batch Consistency
Register Now: Introducing Super Refined™ Poloxamer 188: Optimized for Mammalian Cell Culture with Exceptional Batch-to-Batch Consistency
Ask the Expert webcasts
ATE Webcasts
Register Now: Introduction to Lonza CHO Media Portfolio: Harnessing Simplicity with the TheraPRO® CHO Media System
Register Now: Introduction to Lonza CHO Media Portfolio: Harnessing Simplicity with the TheraPRO® CHO Media System
Ask the Expert webcasts
ATE Webcasts
Register Now: Out of the Box Computer Software Assurance with ValGenesis VLMS
Register Now: Out of the Box Computer Software Assurance with ValGenesis VLMS
Insider News
See all
Dec 2 - Dec 5, 2024
The European Cell and Gene Therapy Congress for Groundbreaking Manufacturing, Commercialisation & Analytical Strategies: World renowned leaders share the latest process development, analytical and market access strategies to improve manufacturing scalability, quality and cost to propel your CGT programmes to commercial success
Learn More

Innovative Technology

Repligen white paper
Sponsored Content
30% Increase in Concentration Accuracies with KrosFlo® RS 30 RPM™ TFF System
30% Increase in Concentration Accuracies with KrosFlo® RS 30 RPM™ TFF System

Oct 25, 2024

Solventum white paper
Sponsored Content
3M™ Harvest RC Centrate Chromatographic Clarifier: Evolving the Role of Clarification in the Biopharmaceutical Manufacturing Process
3M™ Harvest RC Centrate Chromatographic Clarifier: Evolving the Role of Clarification in the Biopharmaceutical Manufacturing Process

Oct 25, 2024

Tosoh AEX Method
Sponsored Content
Improved Safety in Ion Exchange Chromatography for Empty/Full Adeno-Associated Virus Analysis
Improved Safety in Ion Exchange Chromatography for Empty/Full Adeno-Associated Virus Analysis

Oct 14, 2024